CCL17 and neoplasm: To explore these inquiries, we analyzed public databases to compare the levels of CD137 highly (CD137hi) expressing-IFNγ-producing CD8+ T cells, IL12-producing M1 cells and CCL17-producing M2 in tumor tissues from five different cancer types, depending on the response to anti-PD-1 treatment.